Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Julien Aesthetics Personalized treatment plan designed around your features and goals Natural-looking results never frozen or artificial Non-surgical with little to no downtime Boosted confidence from feeling proportionate and refreshed Long-lasting results with safe, FDA-approved fillers What to Expect During Treatment Consultation Our injectors evaluate your facial structure and discuss your goals
Jayedi A, Rashidy-Pour A, Parohan M, Zargar MS, Shab-Bidar S
While injectable GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment landscape for obesity and type 2 diabetes, their reliance on subcutaneous injection remains a significant barrier to broader adoption